AGM/EGMApr 28, 2026, 04:52 PM
ANIK to Hold AGM June 18; Proposes Equity Plan Share Increases
AI Summary
Anika Therapeutics, Inc. will hold its Annual Meeting of Stockholders virtually on June 18, 2026, to elect three Class III Directors, ratify Deloitte & Touche LLP as auditor, approve 2025 executive compensation, and amend two equity incentive plans. The company proposes increasing authorized shares under the 2017 Omnibus Incentive Plan by 475,000 and the 2021 Employee Stock Purchase Plan by 200,000. For 2025, Anika reported $112.8 million in total revenue, $11.2 million in operating cash flow, and $4.4 million in free cash flow, with Commercial Channel revenue growing 15% year-over-year.
Key Highlights
- Annual Meeting of Stockholders to be held virtually on June 18, 2026.
- Proposes increasing 2017 Omnibus Incentive Plan shares by 475,000 to 6,235,000.
- Proposes increasing 2021 Employee Stock Purchase Plan shares by 200,000 to 400,000.
- Reported 2025 total revenue of $112.8 million.
- Generated $11.2 million in operating cash flow and $4.4 million in free cash flow for 2025.
- Commercial Channel revenue grew 15% year-over-year in 2025, and 22% in Q4.
- Integrity Implant System utilization and revenue more than doubled in 2025.
- William R. Jellison and Glenn R. Larsen, Ph.D. resigned from the Board.